Table 8

Medium dose of GC, the medium number of oral ulcers (OU), the Physician Global Assessment and the Patient Global Assessment at baseline and at the end of the follow-up period

	ADA		IFX		Total		Test for mean	Test for median
	Mean±SD	Median (25–75 percentile)	Mean±SD	Median (25–75 percentile)	Mean±SD	Median (25–75 percentile)	P value	P value
Medium dose of GC at baseline	15.83±11.41	10 (7.5 to 25)	13.41±11.69	10 (7.5 to 10)	14.5±11.48	10 (7.5 to 20)	0.514	0.333
Medium dose GC at the end of follow-up	3.89±3.12	3.75 (2.5 to 5)	3.86±5.51	2.5 (0 to 5)	3.88±4.54	2.5 (0 to 5)	0.986	0.449
Diff. medium dose of GC follow-up vs baseline	−11.94±12.38	−7.5 (−22.5 to −2.5)	−9.55±12.95	−6.88 (−10 to −2.5)	−10.63±12.6	−7.5 (−16.25 to −2.5)	0.556	0.652
Medium number of OU at baseline	1.83±0.92	2 (1 to 2)	1.73±0.7	2 (1 to 2)	1.78±0.8	2 (1 to 2)	0.682	0.872
Medium number of OU at the end of follow-up	0.44±0.51	0 (0 to 1)	0.55±0.67	0 (0 to 1)	0.5±0.6	0 (0 to 1)	0.602	0.757
Diff. medium number OU follow-up vs baseline	−1.39±0.7	−1 (−2 to −1)	−1.18±0.66	−1 (−1 to −1)	−1.28±0.68	−1 (−1.5 to −1)	0.344	0.39
Physician Global Assessment at baseline	72.5±12.98	72.5 (65 to 80)	73.18±17.08	80 (65 to 80)	72.88±15.19	77.5 (65 to 80)	0.89	0.647
Physician Global Assessment at the end of follow-up	14.72±19.74	5 (0 to 20)	19.05±17.65	10 (10 to 25)	17.05±18.52	10 (0 to 25)	0.475	0.213
Diff. Physician Global Assessment follow-up vs baseline	−57.78±24.27	−60 (−75 to −40)	−52.86±30.89	−60 (−70 to −40)	−55.13±27.78	−60 (−75 to −40)	0.588	0.702
Patient Global Assessment at baseline	79.44±16.53	90 (70 to 90)	80±14.47	80 (70 to 90)	79.75±15.23	80 (70 to 90)	0.91	0.901
Patient Global Assessment at the end of follow-up	16.67±20	7.5 (0 to 30)	19.32±16.64	20 (5 to 30)	18.13±18.03	15 (0 to 30)	0.65	0.355
Diff. Patient Global Assessment follow-up vs baseline	−62.78±27.98	−65 (−85 to −55)	−60.68±26.65	−65 (−75 to −50)	−61.63±26.92	−65 (−82.5 to −50)	0.81	712

ADA, adalimumab; GC, glucocorticoids; IFX, infliximab.